Development of chemical compounds capable of suppressing tumor progression is a perspective strategy of cancer treatment. Heterocyclic compounds possess a broad spectrum of biological activities, including anticancer one. According to the previous results of in silico modeling maleimide derivative 1-(4-Cl-benzyl)-3-Cl-4-(CF$_3$-phenylamino)-1H-pyrrole-2,5-dione (MI-1) has a potential effect as an inhibitor of tyrosine protein kinases. The present study was aimed at in vitro evaluation of MI-1 cytotoxic effects toward tumor cells of various lines. The viability of tumor cells after incubation with MI-1 was measured by means of 3,4,5-dimethylthiazol-2-yl-2,5-diphenyl-tetrazolium bromide (MTT) test. The MI-1 compound was shown to be toxic for a majority of studied tumor cell lines with IC$_{50}$ value ranging from 0.8 to 62.2 μg/ml depending on the tissue origin of cells. The most prominent effect of MI-1 towards human cervix carcinoma (KB3-1 and KBC-1) cells with six times higher toxicity towards the multidrug resistant sub-line KBC-1 cells comparing with the action of Doxorubicin was demonstrated. MI-1 inhibited the viability of human pancreatic, hepatocarcinoma, and colon carcinoma cells only in high doses, while human and rat glioblastoma cells were not sensitive to MI-1. Thus, the MI-1 anticancer activity dropped in the following rank of tumor cells: cervix > breast > pancreatic carcinoma > liver carcinoma > colon carcinoma > glioblastoma. Experiments on replacement of methyl green dye from DNA-methyl green complex showed that MI-1 intercalated into DNA molecule structure. The increase of the amount of the additional band of super-spiral DNA in the presence of MI-1 was revealed by means of DNA retardation at electrophoresis in the agarose gel and this effect was more pronounced than the effect of doxorubicin. The data presented indicate a new DNA-targeting mechanism of maleimide derivative 1-(4-Cl-benzyl)-3-Cl-4-(CF$_3$-phenylamino)-1H-pyrrole-2,5-dione anticancer action.

**Keywords:** 1-(4-Cl-benzyl)-3-Cl-4-(CF$_3$-phenylamino)-1H-pyrrole-2,5-dione, anticancer activity, MTT.
rats [9] and possessed low general toxicity in laboratory animals [7, 10, 11].

Protein kinases are enzymes that regulate different cellular processes including cell proliferation, differentiation and migration, cell cycle regulation, and metabolism [2, 12]. A deregulation of these processes via mutations or over-expression of kinases leads to various diseases [13, 14]. Kinases play an important role in the carcinogenesis and metastases of different types of cancer [2, 15]. Thus, a development of protein kinases inhibitors is of great interest for the cancer treatment. A number of protein kinases inhibitors, such as imatinib [16], benzotriazines, quinazolines, pyrazolopyrimidines, imidazo[1,5-alpyrazines, pyridopyrimidinones and other heterocycles, ATP-phospho-peptide conjugates have been developed and investigated for the treatment of cancer [12, 17-19].

It is obvious that the multifunctional anticancer agents affecting different bio-molecules and biological processes could be more efficient treatment remedies comparing to such agents with only one bio-target in the tumor cells. The aim of our study was to carry out a search for novel biological targets at the cytotoxic action of maleimide derivative MI-1, namely evaluating a possibility that DNA molecule could also be such target. Besides, we addressed a potential toxic effect of MI-1 towards mammalian tumor cell lines, specifically the drug-resistant tumor cells not studied earlier.

Materials and Methods

Compounds under study. The synthesis of maleimide derivate 1-(4-Cl-benzil)-3-Cl-4-(CF₃-phenylamino)-1H-pyrrole-2,5-dione (MI-1, Fig. 1) was carried out by successive chemical transformations, as described previously [6, 11]. The stock solution of MI (10 mg/ml) was prepared in the Dimethyl Sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO, USA), and before adding to the cultured cells, further solutions were prepared using culture medium. Doxorubicin (Actavis S.R.L., Bucharest, Romania) was used as a positive control anticancer drug.

Cell culture and anti-proliferative MTT assay. Human pancreatic ductal adenocarcinoma Capan-1 cells, human epidermoid cervix carcinoma KB3-1 cells and its colchicine-resistant sub-line KBC-1, that is characterized by over-expression of plasma membrane P-glycoprotein, were donated by a Collection of the Institute for Cancer Research at Vienna Medical University (Vienna, Austria). Human breast adenocarcinoma MCF-7 and MDA231, human colon carcinoma HCT116 cells, human hepatocarcinoma HepG2 cells were obtained from the Collection at the Institute of Experimental Pathology, Oncology and Radiobiology (Kyiv, Ukraine). Human glioblastoma cells of U251, U373 and T98G lines, rat glioma C6 cells were obtained from a Collection at the Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine (Kyiv, Ukraine). Cells were grown in RPMI-1640 (Biowest, Nuaille, France) or Dulbecco’s-modified Eagle’s medium (DMEM, Biowest, Nuaille, France) culture medium supplemented with 10% fetal bovine serum (Biowest, Nuaille, France) at the standard conditions (37 °C in an atmosphere of 5% CO₂).

The MI-1 cytotoxicity towards tumor cells in vitro was measured using colorimetric MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Sigma-Aldrich, USA) assay for estimating functional activity of the treated cells. Cells were plated at 5,000 cells/well (substrate-dependent cells) or 15,000 cells/well (suspension cells) in 100 µl of 96-well plates and allowed to grow overnight. The MI-1 or Doxorubicin at 1, 10, and 100 µg/ml was added in 100 µl of cultural medium, and cells were incubated for the next 72 h. After that, the MTT assay was performed according to the manufacturer’s recommendations (Sigma-Aldrich, St. Louis, MO, USA). The absorbance of formazan was measured by an Absorbance Reader BioTek ELx800 (BioTek Instruments, Inc., Winooski, VT, USA). The IC₅₀ level of MI-1 was calculated as the drug concentration that reduced cell viability by 50% [20].

Electrophoretic gel retardation assay of plasmid DNA. Plasmid DNA (1 µg) pEGFPc-1 (Clontech, Mountain View, California, USA) was mixed with 2 µl of MI-1 (1; 10; 100 µg/ml), and Dox (1 and
10 μg/ml) in 18 μl of 0.9% sodium chloride (Artemium, Lviv, Ukraine) at room temperature for 1 h. Prepared mixture was analyzed by electrophoresis in 1% agarose gel (Lachema, Brno, Czech Republic) with 1× Tris acetate (TAE) buffer containing 1 μg/ml of Ethydium bromide (Sigma-Aldrich, St. Louis, Missouri, USA) for approximately 1 h at a constant voltage of 70 V. The trans-illuminator (MacroVue UV-20, Hoeffer, Troy, Michigan, USA) was used for visualization of plasmid DNA [21].

**DNA intercalation assay using methyl green replacement.** Methyl green binds to DNA with an absorption maximum at 642 nm. Free methyl green does not show absorption at this wavelength, while the compounds that bind/intercalate with DNA replaced methyl green from the complex of methyl green–DNA and decreased the optical density at 642 nm wave length. 485 μl of salmon sperm DNA (50 μg/ml, Sigma-Aldrich, St. Louis, Missouri, USA) were incubated for 1 h at 37 °C with 15 μl of methyl green (Sigma-Aldrich, St. Louis, Missouri, USA) solution (1 mg/ml in water). 500 μl of MI-1 (1 and 10 μg/ml), or Dox (10 μM) were added to methyl green-DNA complex and incubated for 2 h at 37 °C in the dark. The Ethydium bromide (EtBr, 1 and 10 μg/ml) was used as a positive control. Absorption of methyl green was measured at 630 nm [22] using a fluorescence plate reader (Absorbance Reader BioTek ELx800, BioTek Instruments, Inc., Winooski, Vermont, USA).

**Data analysis.** The results were analyzed and illustrated using Origin software (version 7). All data are presented as the mean (M) ± standard deviation (SD) of three independent replications. A t test was used for statistical analysis. Statistical significance was identified at P ≤ 0.05.

**Results and Discussion**

**Cytotoxicity study.** In this study, human tumor cells of different tissue origin, namely leukemia, cervix, breast, glioblastoma, and pancreas, were subjected to the action of the MI-1 compound applied in three doses - 1, 10, and 100 μg/ml. The MTT assay was used for evaluation of the antineoplastic activity of the MI-1. It was found that the MI-1 inhibited growth of human breast adenocarcinoma MCF-7 cells with the IC₅₀ of 9.7 μg/ml (Fig. 2, Table), while the Doxorubicin demonstrated higher cytotoxicity towards these tumor cells (IC₅₀ = 1.9 μg/ml). However, human breast adenocarcinoma cells of the MDA231 line were relatively resistant to the action of MI-1 in dose up to 50 μg/ml (Fig. 2, Table).

Rapid development of the multidrug resistance is one of the main problems in cancer treatment. Among the main mechanisms of such resistance are the over-expression of the ABC transporters on plasma membrane, mutations in the BRCA gene, DYNLL1 gene and other mechanisms that promote drug inactivation and/or degradation [23, 24]. In this study, we compared the anti-neoplastic activity of the MI-1 towards human epidermoid cervix carcinoma cells of KB3-1 line and its colchicine-resistant KBC-1 sub-line that is characterized by P-glycoprotein over-expression. The MI-1 proved to be six times more effective in growth inhibition of KBC-1 cells (IC₅₀ = 0.8 μg/ml), comparing to Doxorubicin (IC₅₀ = 4.8 μg/ml), while at targeting wild type KB3-1 line, the picture was opposite and these cells were more sensitive to the Doxorubicin (IC₅₀ = 0.3 μg/ml) than to the MI-1 (IC₅₀ = 7.5 μg/ml) (Fig. 2, Table). Thus, the MI-1 was shown to be capable of circumventing drug resistance mechanism dependent on P-glycoprotein over-expression.

The MI-1 also inhibited growth of human pancreatic ductal adenocarcinoma Capan-1 cells (IC₅₀ = 18.0 μg/ml), human hepatocarcinoma HepG2 cells (IC₅₀ = 33.5 μg/ml), and human colon cancer HCT116 cells (IC₅₀ = 62.2 μg/ml) (Fig. 3, Table). These concentrations are much higher than those

![Fig. 2. The anti-proliferative activity of 1-(4-Cl-benzil)-3-Cl-4-(CF₃-phenylamino)-1H-pyrrole-2,5-dion (MI-1) towards human breast adenocarcinoma (MCF-7 and MDA 231) cells, human epidermoid cervix carcinoma cells of KB3-1 line and its colchicine-resistant KBC-1 sub-line. Cell viability was examined using the MTT assay after 72 h cell exposure to the MI-1 compound](image)
Cytotoxicity indicator (IC$_{50}$) of 1-(4-Cl-benzil)-3-Cl-4-(CF$_3$-phenylamino)-IH-pyrrole-2,5-dion (MI-1) and Doxorubicin (Dox) at targeting human tumor cells of different tissue origin

| Cell line   | IC$_{50}$ µg/ml | IC$_{50}$ µg/ml |
|-------------|-----------------|-----------------|
| KB3-1       | 7.5             | 0.3             |
| KBC-1       | 0.8             | 4.8             |
| Capan-1     | 18.0            | 0.2             |
| Hep G2      | 33.5            | 0.6             |
| HCT 116 wt  | 62.2            | 0.8             |
| MCF-7       | 9.7             | 1.9             |
| MDA231      | >50             | 1.6             |
| U251        | >50             | 0.4             |
| U373        | >50             | 0.7             |
| T98G        | >50             | 0.4             |
| C6          | >50             | 1.3             |

mentioned above for inhibition of human epidermoid cervix carcinoma cells of KB3-1 line and its colchicine-resistant KBC-1 sub-line. These doses of the MI-1 compound are also much higher than the cytotoxic doses of the Doxorubicin (Table).

Human glioblastoma cells of U251, U373, and T98G and rat glioma C6 lines were relatively nonsensitive to the MI-1 action, and the IC$_{50}$ level was above 50 µg/ml, while IC$_{50}$ for Doxorubicin indicated high cytotoxic effect of the last chemotherapeutic drug (Fig. 4, Table).

Study of interaction of the MI-1 with DNA. The 1-(4-Cl-benzil)-3-Cl-4-(CF$_3$-phenylamino)-IH-pyrrole-2,5-dion (MI-1) was designed in silico as an inhibitor of tyrosine kinases [3] that are important targets in the action of many anticancer drugs [4, 5]. However, other biological targets of the MI-1’s effect cannot be excluded. In order to address such possibility, we have suggested that the DNA molecule could be another target that is used at the cytotoxic action of the MI-1 compound. It is known that several FDA approved anticancer therapeutics, such as doxorubicin, cisplatin, bleomycin, chlorambucil, etoposide, mephalan can bind the DNA and in such a way affect its structure and functions [22, 25, 26]. Besides, the Reactive Oxygen Species (ROS) induced in treated cells by the above noted anticancer drugs can cause the oxidative damage of DNA molecule, and thus, enhance the efficacy of cytotoxic action of these drugs [27]. The DNA-interacting agents can also affect the cell-cycle checkpoints leading to their block [26].

It was shown that the MI-1 used at 1 and 10 µM concentrations replaced the methyl green dye in the DNA-methyl green complex by 21.2 and 16.5%,
respectively (Fig. 5). The Doxorubicin (10 μg/ml) also known as the DNA-intercalating agent [26], replaced by 72.1% the methyl green in its complex with the DNA, while the Ethydium bromide (1 and 10 μg/ml), a well-known DNA-intercalating agent, demonstrated 54.1 and 80.1% replacement of the methyl green, respectively (Fig. 5).

As one can see on Fig. 6 (lanes 4-6), plasmid DNA was not retarded at electrophoresis by the MI-1 used in 1, 10 and 100 μg/ml doses, while the Doxorubicin used in 1 and 10 μg/ml doses as a positive control, retarded the electrophoretic mobility in the agarose gel of the supercoiled form of plasmid DNA (Fig. 6, lane 2). It should be noted that three bands of plasmid DNA were detected after its 1 h incubation with the MI-1 compound that suggests its potential to induce supercoiling of the DNA molecule that could cause its functional deterioration. Taken together, the results of the methyl green replacement assay and the results of the electrophoretic retardation study of plasmid DNA definitely indicate a possibility of a direct interaction of the MI-1 with the DNA molecule. However, additional experiments are necessary in order to confirm or exclude a specificity of such binding of the MI-1 to the DNA.

In this study, we detected that the maleimide derivative 1-(4-Cl-benzil)-3-Cl-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione (MI-1 compound) possesses a remarkable cytotoxic activity towards several human tumor cell lines with the inhibition indicator (IC50) ranging from 0.8 to 62.2 μg/ml for different cell lines. The most prominent cytotoxic effect was demonstrated by the MI-1 towards human cervix carcinoma cells of KB3-1 and KBC-1 lines. It should be stressed that the MI-1 showed six times higher toxicity towards the multidrug resistant KBC-1 subline of these cells, comparing with the cytotoxic action of doxorubicin. The MI-1 also inhibited the viability of human pancreatic, hepatocarcinoma, colon carcinoma cells, however, did that at high doses than for the above mentioned human cervix carcinoma cells. Human glioblastoma cells were poorly sensitive to a cytotoxic action of the MI-1. Thus, the anti-neoplastic activity of the MI-1 dropped in the
following rank of cells: cervix carcinoma > breast carcinoma > pancreatic carcinoma > liver carcinoma > colon carcinoma > glioblastoma.

In addition to cytotoxicity study, the investigation of the interaction of the MI-1 with the DNA molecule was carried out using DNA intercalation and DNA retardation tests. The results of both of these tests indicate a possibility of direct interaction of the MI-1 with the DNA molecule. These results allow one to suggest that DNA damaging could be an additional mechanism of induction of tumor cell death, besides earlier proposed mechanism of inhibition of tyrosine-specific protein kinases. However, further investigations are needed to confirm experimentally any or both of these mechanisms of the potential anticancer activity of the synthesized MI-1 compound.

Conflict of interest. Authors have completed the Unified Conflicts of Interest form at http://ukrbiochemjournal.org/wp-content/uploads/2018/12/coi_disclosure.pdf and declare no conflict of interest.

Acknowledgement. This research was mainly supported by the Ministry of Education and Science of Ukraine grant (“Novel hybrid anti-tumor and anti-inflammatory nanocomplexes based on pyrroles and C60 fullerenes: development, properties, pharmacodynamics and toxicological characteristics” (Registration No 0119U100331). Partially, the research was supported by the International Research and Innovation in Medicine Program, Cedars-Sinai Medical Center (Los-Angeles, USA) and the Association for Regional Cooperation in the Fields of Health, Science and Technology. The authors thank Prof. Walter Berger (Institute of Cancer Research, Medical University of Vienna, Vienna, Austria) for kind donating human pancreatic ductal adenocarcinoma Capan-1 cells, human epidermoid cervix carcinoma cells of KB3-1 line and its colchicine-resistant KBC-1 subline.

ЦИТОТОКСИЧНА ДІЯ ПОХІДНОГО МАЛЕЇМІДУ 1-(4-СІ-БЕНЗІЛИ) -3-ХЛОРО-4-(CF<sub>3</sub>-ФЕНИЛАМІНО)-1H-ПІРОЛ-2,5-ДІОНУ НА ПУХЛІННИ КЛІТИНИ І ЙОГО ЗДАТНІСТЬ ДО ВЗАЄМОДІЇ З ДНК

H. С. Фінюк<sup>1,2</sup>, І. І. Івасечко<sup>1</sup>, О. Ю. Ключівська<sup>1</sup>, Г. М. Кузнєцова<sup>1</sup>, В. К. Рибалченко<sup>1</sup>, Р. С. Стойка<sup>1,2,3</sup>

<sup>1</sup>Інститут біології клітини НАН України, Львів;  
<sup>2</sup>Львівський національний університет імені Івана Франка, Україна;  
<sup>3</sup>Київський національний університет імені Тараса Шевченка, Україна;  
<sup>2,3</sup>e-mail: stoika@cellbiol.lviv.ua

Розробка хімічних сполук, здатних пригнічувати ріст пухлин є перспективною стратегією в лікуванні раку. Гетероциклічні сполуки виявляють широкий спектр біологічної дії, в тому числі протиракову активність. Попередні результати моделювання in silico показали, що похідне малеїміду 1-(4-Cl-бензил)-3-Cl-4-(CF<sub>3</sub>-феніламіно)-1H-пірол-2,5-дійон (MI-1) виявляє потенційний ефект як інгібітор тирозин-специфічних протеїнкіназ. Метою роботи було визначити in vitro цитотоксичні ефекти MI-1 щодо пухлинних клітин різних ліній. Життєздатність пухлинних клітин після інкубації з MI-1 визначали за допомогою 3,4,5-диметилтіазол-2-іл-2,5-дифеніл-тетразоліум броміду тесту (MTT-тесту). Показано, що сполука MI-1 є токсичною для більшості досліджуваних пухлинних клітинних ліній із IC<sub>50</sub> в межах від 0,8–62,2 мкг/мл залежно від тканинного походження клітин. Найвиразніший ефект MI-1 спостерігали на клітинах карциноми шийки матки людини (KB3-1 і KBC-1). Так, MI-1 виявляла в шість разів більшу цитотоксичність щодо медикаментозно стійкої сублінії клітин KBC-1 порівняно з дією доксорубіцину.
Сполука МІ-1 пригнічувала ріст клітин раку підшлункої залози, гепатокарциноми і карциноми товстої кишки людини тільки у високих концентраціях. Клітини гіліобластоми людини та шурув були нечутливими до дії МІ-1. Протипухлинна активність МІ-1 знижувалася в такому порядку: 1. Такий ефект MI-1 був істотнішим, ніж ефект суперспіральної форми ДНК у присутності МІ-1, показано збільшення кількості додаткової фракції тодом ДНК електрофорезу в агарозному гелі від 20% із комплексу ДНК-метиловий зелений. МІ-1 здатні заміщати метиленовий зелений (ближко 50% з усіх клітин). ДНК що було підтверджено здатністю цієї сполуки заміщати метиленовий зелений (ближко 50%) із комплексу ДНК-метиловий зелений. Методом ДНК електрофорезу в агарозному гелі виявлено збільшення кількості додаткової фракції суперспіральної форми ДНК у присутності МІ-1. Такий ефект МІ-1 був істотнішим, ніж ефект доксорубіцину. Представлені дані свідчать про новий, асоційований із взаємодією з ДНК, метод ДНК електрофорезу в агарозному гелі виявлено збільшення кількості додаткової фракції суперспіральної форми ДНК у присутності МІ-1. Такий ефект МІ-1 був істотнішим, ніж ефект доксорубіцину. Представлені дані свідчать про новий, асоційований із взаємодією з ДНК, механізм протипухлинної дії похідного малеїміду 1-(4-Cl-бензил)-3-Cl-4-(CF₃-феніламіно)-1H-пірол-2,5-діону.

Ключові слова: 1-(4-Cl-бензил)-3-хлор-4-(CF₃-феніламіно)-1H-пірол-2,5-діон, протипухлинна активність, МТТ.

References

1. El-Moghazy SM, George RF, Osman EEA, Elbatrawy AA, Kissova M, Colombo A, Crespan E, Maga G. Novel pyrazolo[3,4-d] pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line. *Eur J Med Chem.* 2016; 123: 1-13.

2. Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and future directions. *Mol Cancer.* 2018; 17(1): 48.

3. Pat. 22204 UA. Compound of 1,4-disubstituted 5-amino-1,2-dihiydropyrrrole-3-one having antiproliferative activity / Dubinina G. G., Volovenko Yu. M. Publ. 25.04.2007.

4. Dubinina GG, Chupryna OO, Platonov MO, Borisko PO, Ostrovskva GV, Tolmachov AO, Shtil AA. In silico design of protein kinase inhibitors: successes and failures. *Anticancer Agents Med Chem.* 2007;7(2):171-188.

5. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. *Nat Rev Cancer.* 2009; 9(11): 28-39.

6. Dubinina GG, Golovach SM, Kozlovsky VO, Tolmachov AO, Volovenko YuM. Antiproliferative action of the new derivatives of 1-(4-R-benzyl)-3-R1-4-(R2-phenylamino)-1H-pyrrol-2,5-dione. *J Organ Pharm Chem.* 2007; 5(1): 39-49. (In Ukrainian).

7. Kuznietsova HM, Lynchak OV, Danylov MO, Kotlyar IP, Rybalchenko VK. Effect of dihydropyrrrole and maleimide derivatives on the state of liver and colon in normal rats and those with colorectal carcinogenesis induced by dimethylhydrazine. *Ukr Biokhim Zhurn.* 2013; 85(3): 74-84. (In Ukrainian).

8. Yablonska S, Lynchak O, Filinska O. Proc. 34th FEBS congress “Manifestation of antiproliferative effects of new kinase inhibitor in respect of normal cell”. Prague, Czech Republic, 2009. P. 352.

9. Kuznietsova HM, Yena MS, Kotlyar IP, Ogloblya OV, Rybalchenko VK. Antiinflammatory effects of protein. *Sci World J.* 2016; 2016: 2145753.

10. Kharchuk IV, Andrukhova OO, Rybal’chenko VK, Andrukhov O. Mechanisms of nephrotoxicity of novel anticancer compound maleimide derivative MI-1. *Fiziol J.* 2013;59(3):50-57. (In Ukrainian).

11. Kuznietsova HM, Dzibuenko NV, Lynchak OV, Tykhoniuk OL, Milokhov DS, Khilya OV, Rybalchenko VK. Hepatoprotective effect of protein kinase inhibitor 1-(4-cl-benzyl)-3-chloro-4-(cf3-phenylamino)-1H-pyrrole-2,5-dione on rats’ acute cholangitis. *Rep Nat Acad Sci Ukr.* 2018; (5): 83-90. (In Ukrainian).

12. Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. *Expert Rev Anticancer Ther.* 2018; 18(12): 1249-1270.

13. Ismail NSM, Ali GME, Ibrahim DA, Elmetwali AM. Medicinal attributes of pyrazolo[1,5-ajpyrimidines based scaffold derivatives targeting kinases as anticancer agents. *Future J Pharm Sci.* 2016; 2(2): 60-70.

14. Köstler WJ, Zielinski CC. Targeting receptor tyrosine kinases in cancer. In Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. New York: Spring, 2015. P. 225-278.

15. Mudgapalli N, Nallasamy P, Chava H, Chava S, Pathania AS, Gunda V, Gorantla S, Pandey MK, Gupta SC, Challagundla KB. The role of...
exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities. *Mol Aspects Med.* 2019; 70: 21-32.

16. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Herend J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med.* 2006; 355(23): 2408-2417.

17. Kumar A, Ahmad I, Chhikara BS, Tiwari R, Mandal D, Parang K. Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities. *Bioorg Med Chem.* 2011; 21(5): 1342-1346.

18. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Scheven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. *J Med Chem.* 2004; 47(27): 6658-6661.

19. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciciri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Inske DE, Inske MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. A small molecule–kinase interaction map for clinical kinase inhibitors. *Nat Biotechnol.* 2005; 23(3): 329-336.

20. Finiuk NS, Ostapiuk YuV, Hreniukh VP, Shalai YaR, Matiyuchuk VS, Obushak MD, Stoika RS, Babsky AM. Evaluation of antiproliferative activity of pyrazolothiazolopyrimidine derivatives. *Ukr Biochem J.* 2018; 90(2): 25-32.

21. Finiuk NS, Ivasechko II, Klyuchivska OYu, Ostapiuk YuV, Hreniukh VP, Shalai YaR, Matiyuchuk VS, Obushak MD, Babsky AM, Stoika RS. Apoptosis induction in human leukemia cells by novel 2-amino-5-benzylthiazole derivatives. *Ukr Biochem J.* 2019; 91(2): 29-39.

22. Filak LK, Mühlgassner G, Jakupec MA, Heffeter P, Berger W, Arion VB, Keppler BK. Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. *J Biol Inorg Chem.* 2010; 15(6): 903-918.

23. Schlacher K. A new road to cancer-drug resistance. *Nature.* 2018; 563(7732): 478-480.

24. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. *Cancers (Basel).* 2014; 6(3): 1880-1892.

25. Palchaudhuri R., Hergenrother PJ. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. *Curr Opin Biotechnol.* 2007; 18(6): 497-503.

26. Hurley LH. DNA and its associated processes as targets for cancer therapy. *Nat Rev Cancer.* 2002; 2(3): 188-200.

27. Mitra S, Nguyen LN, Akter M, Park G, Choi EH, Kaushik NK. Impact of ROS generated by chemical, physical, and plasma techniques on cancer attenuation. *Cancers (Basel).* 2019; 11(7): 1030.